Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.14 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
Chapter 5 Market Segmentation, By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
Chapter 6 Market Segmentation, By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Mitsubishi Tanabe
9.2. AstraZeneca
9.3. Astellas Pharma
9.4. Takeda
9.5. Emergent BioSolutions
9.6. Pfizer
9.7. Sanofi
9.8. GlaxoSmithKline
9.9. Merck & Co.
9.10. Johnson & Johnson
9.11. CSL
9.12. Emergent Biosolutions
9.13. Serum Institute
9.14. MedImmune, LLC
9.15. Bavarian Nordic
Chapter 10 Market Insights
10.1 Insights of Industry Experts
10.2 Analyst Opinion (Market Understanding)
10.3 Investment Opportunities
Chapter 11 Appendix
11.1 List of Tables
11.2 List of Figures
